A new plant-based coronavirus vaccine has shown promising results in phase three clinical trials. The drug is being developed by Medicago, a biopharmaceutical company headquartered in Quebec City. The company has received regulatory approval from Health Canada to market the drug. This is a significant development for patients who have been at risk of developing the disease. However, the development of this vaccine is not without risk.
The new plant-based coronavirus vaccine has been developed by researchers at GlaxoSmithKline. The trial has shown that the drug has 71 percent efficacy against disease caused by the COVID-19 virus. Despite the challenges involved in the development of the product, the company hopes to develop additional versions of the vaccine to expand its use in the future. This is a major step forward for patients who are at risk of developing the disease.
The company has made it possible to develop a plant-based vaccine against the COVID-19 virus. The new plant-based vaccine is an improvement over previous versions and may lead to a lower cost. It also requires less greenhouse space, which may not be a viable option for all countries. Additionally, it has been developed to work with multiple variants of the COVID-19 virus.
Medicago said it would file the adjuvanted plant-based coronavirus vaccine for regulatory approval with Health Canada, the FDA and others.